Serum adiponectin acutely after an ischemic stroke: Implications for a long-lasting, suppressed anti-inflammatory role

Acta Neurologica Scandinavica

Volumn 121, Issue 4, 2010, Pages 277-284

  Marousi, S ^a   Theodorou, G ^a   Karakantza, M ^a   Papathanasopoulos, P ^a   Ellul, J ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Acute phase inflammation; Adiponectin; Ischemic stroke

Indexed keywords

ADIPONECTIN;

ACUTE DISEASE; ADIPONECTIN BLOOD LEVEL; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADIPONECTIN; AGED; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; STROKE; TIME FACTORS;

EID: 77749248920     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01231.x     Document Type: Article

References (38)

1. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996 271 : 10697 10703.
2. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996 221 : 286 289.
3. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 2004 89 : 87 90.
4. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000 20 : 1595 1599.
5. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999 257 : 79 83.
6. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004 27 : 2450 2457.
7. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003 16 : 72 5.
8. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007 380 : 24 30.
9. Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007 56 : 459 467.
10. Matarese G, Mantzoros C, La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des 2007 13 : 3676 3680.
11. Krakoff J, Funahashi T, Stehouwer CD et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003 26 : 1745 1751.
12. Bruun JM, Lihn AS, Verdich C et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003 285 : E527 33.
13. Nilsson PM, Engstrom G, Hedblad B et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006 26 : 2758 2762.
14. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke 2005 36 : 2577 2582.
15. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007 92 : 571 576.
16. Soderberg S, Stegmayr B, Stenlund H et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004 256 : 128 136.
17. Matsumoto M, Ishikawa S, Kajii E. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke 2008 39 : 323 328. (Pubitemid 351619450)
18. Stott DJ, Welsh P, Rumley A et al. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol 2009 38 : 253 261.
19. Chen MP, Tsai JC, Chung FM et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005 25 : 821 826.
20. Sasaki M, Kawano T, Saito T et al. Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders. Am J Med Sci 2007 333 : 140 144.
21. Bonita R. Epidemiology of stroke. Lancet 1992 339 : 342 344.
22. Jones WJ, Williams LS, Meschia JF. Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke 2001 32 : 2232 2236.
23. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002 51 : 2968 2974.
24. Clasen R, Schupp M, Foryst-Ludwig A et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005 46 : 137 143.
25. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003 42 : 76 81.
26. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004 110 : 3687 3692.
27. Adams HP Jr., Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 24 : 35 41.
28. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003 49 : 650 652.
29. Nishizawa H, Shimomura I, Kishida K et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002 51 : 2734 2741.
30. Altman DG. Statistics and ethics in medical research: III How large a sample? Br Med J 1980 281 : 1336 1338.
31. Whitley E, Ball J. Statistics review 4: sample size calculations. Crit Care 2002 6 : 335 341.
32. Kumada M, Kihara S, Ouchi N et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004 109 : 2046 2049.
33. Intiso D, Zarrelli MM, Lagioia G et al. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004 24 : 390 396.
34. Waje-Andreassen U, Krakenes J, Ulvestad E et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005 111 : 360 365.
35. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004 279 : 28670 28674. (Pubitemid 38900150)
36. Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004 94 : e27 31.
37. Nishimura M, Izumiya Y, Higuchi A et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008 117 : 216 223.
38. Efstathiou SP, Tsioulos DI, Tsiakou AG, Gratsias YE, Pefanis AV, Mountokalakis TD. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005 36 : 1915 1919.